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Abstract The APOE ε2/3/4 genotype has been associ-
ated with low-density lipoprotein cholesterol (LDL-C)
and Alzheimer disease. However, evidence for associa-
tions with measures of cognitive performance in adults
without dementia has been mixed, as it is for physical
performance. Associations may also be evident in other
genotypes implicated in LDL-C levels. As part of the
Healthy Ageing across the Life Course (HALCyon)
collaborative research programme, genotypic informa-
tion was obtained for APOE ε2/3/4, rs515135 (APOB),
rs2228671 (LDLR) and rs629301 (SORT1) from eight
cohorts of adults aged between 44 and 90+years. We
investigated associations with four measures of cogni-
tive (word recall, phonemic fluency, semantic fluency
and search speed) and physical capability (grip strength,
get up and go/walk speed, timed chair rises and ability to
balance) using meta-analyses. Overall, little evidence
for associations between any of the genotypes and mea-
sures of cognitive capability was observed (e.g. pooled
beta for APOE ε4 effect on semantic fluency z score=
−0.02; 95 % CI=−0.05 to 0.02; p value=0.3; n=
18,796). However, there was borderline evidence within
studies that negative effects of APOE ε4 on nonverbal
ability measures become more apparent with age. Few
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genotypic associations were observed with physical ca-
pability measures. The findings from our large investi-
gation of middle-aged to older adults in the general
population suggest that effects of APOE on cognitive
capability are at most modest and are domain- and age-
specific, while APOE has little influence on physical
capability. In addition, other LDL-C-related genotypes
have little impact on these traits.
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Introduction
Higher levels of low-density lipoprotein cholesterol
(LDL-C) have been associated with a number of age-
related conditions, including increased risk of coronary
heart disease (Wilson et al. 1998). Although modifica-
tion by diet (Kelley et al. 2012) and pharmacological
interventions (Law et al. 2003) is possible, LDL-C is
partly heritable (Matteini et al. 2010), with several iden-
tified genetic variants contributing to its interindividual
variability. Among these, the ε2, ε3 and ε4 alleles of the
APOE gene are probably the most widely studied.
Encoding apolipoprotein E and playing a key role in
lipid metabolism (Mahley and Rall 2000), several stud-
ies have observed that carriers of the APOE ε2 and ε4
alleles display lower and higher, respectively, levels of
LDL-C compared with the most common ε3/ε3 geno-
type (Bennet et al. 2007). In addition, it has been long
established that carriers of the ε2 alleles are at lower
risk, and those with the ε4 alleles are at higher risk of
Alzheimer disease (Bertram et al. 2007). Among cogni-
tively healthy individuals, there is also evidence from
many, though not all studies, that carriers of the ε4 allele
perform worse in some cognitive tests and that these
effects may be more pronounced in older populations
(Caselli et al. 2009; Wisdom et al. 2011; Davies et al.
2014). For instance, there is little evidence to support the
influence of the APOE genotype on cognitive measures
in children and young people (Taylor et al. 2011; Ihle
et al. 2012), though there is some mixed evidence for its
influence in middle-aged (Zhao et al. 2005; Bunce et al.
2011) and older (Deary et al. 2004a) adults. In addition,
there is some evidence from longitudinal studies that ε4
carriers experience greater cognitive decline in mid-
(Blair et al. 2005) and later (Schiepers et al. 2012) life.
APOE may also have a role in ageing phenotypes more
generally, with other associations including triglycer-
ides, apolipoproteins, C-reactive protein (Khan et al.
2013), type 2 diabetes (Anthopoulos et al. 2010), lon-
gevity (McKay et al. 2011; Nebel et al. 2011) and
Parkinson disease (Lill and Roehr).
Given that the observed associations between cogni-
tive and physical performance measures (Deary et al.
2006; Clouston et al. 2013) may be a result of genetic
influences on shared age-related pathways simulta-
neously leading to the impairment of both (Johnson
et al. 2009), it has been hypothesised that the pleiotropic
APOE genotype may also affect physical performance.
However, to date, investigations into associations be-
tween APOE and physical performance have also been
inconsistent, with the ε4 allele reported to be associated
with slower gait speeds (Melzer et al. 2005), but not
with fitness (Deary et al. 2006), frailty (Rockwood et al.
2008), or grip strength (Vasunilashorn et al. 2013) and
mixed findings for disability (Hyman et al. 1996;
Kulminski et al. 2008) and chair stands speed (Melzer
et al. 2005; Vasunilashorn et al. 2013) in middle-aged
and older adults.
Therefore, further investigations into associations be-
tween APOE and cognitive and physical performance
measures are required. It is also of interest to examine
whether any such effects are related to an effect on LDL-
C. Given the conflicting evidence for associations be-
tween levels of LDL-C and cognitive (Yaffe et al. 2002;
Packard et al. 2007) and physical performance measures
(Walston et al. 2002; Blain et al. 2012), investigations of
other LDL-C-related genotypes may help to elucidate
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whether or not any effects are unique to APOE.
Therefore, we analysed data from 23,916 participants
aged between 44 and 90+ from eight UK cohorts as part
of the HALCyon research programme (Healthy Ageing
across the Life Course; www.halcyon.ac.uk) to
investigate associations between the APOE genotype
and objective measures of physical and cognitive
capability, the capacity to undertake the physical and
mental tasks of daily living. We also explored whether
any effects are also demonstrated for other genotypes
robustly associated with LDL-C (rs515135 (APOB),
rs2228671 (LDLR) and rs629301 (SORT1)) in
genome-wide association studies (Aulchenko et al.
2009; Teslovich et al. 2010) (GWAS).
Methods
Study populations
Participants from eight UK cohorts of the HALCyon
programme were included in this report. The
National Child Development Study (NCDS) has
followed up all individuals born in England,
Scotland and Wales during 1 week in March 1958.
In 2002–2004, a Biomedical Survey was conducted
during home visits by a research nurse. Following
informed consent, DNA was extracted from 8,017
participants aged 44–45 years; the sample with
immortalised cell line culture (n=7,526) is used here.
In 2008-2009, an eighth sweep was carried out
during which cognitive performance tests were con-
ducted (Brown and Dodgeon 2010). Further details
of the study are available elsewhere (Power and
Elliott 2006).
The Medical Research Council National Survey of
Health and Development (NSHD) comprises partici-
pants sampled from all births in a week in March
1946 and followed up since. In 1999, at age 53 years,
men and women were visited by a research nurse and
DNA was extracted from 2,756 members of the co-
hort. Details of the data collected and the several
phases of the study are available on the cohort’s
website (www.nshd.mrc.ac.uk) and elsewhere
(Wadsworth et al. 2006).
TheWhitehall II study targeted all civil servants aged
between 35 and 55 years working in London in 1985–
1988. In 2002–2004 (phase 7), the genetics study was
established and DNA was extracted from 6,156
participants. Details of the study design and data col-
lected have been described elsewhere (Marmot and
Brunner 2005).
The Caerphilly Prospective Study (CaPS) re-
cruited 2,512 men aged between 45 and 59 years
in 1979–1983 from the town of Caerphilly, South
Wales and its surrounding villages. Blood samples
were collected at baseline and at each of the four
follow-ups (phase II, 1984–1988; phase III, 1989–
1993; phase IV, 1993–1997 and phase V, 2002–
2004). Further details are available on the cohort’s
website (http://www.bris.ac.uk/social-community-
medicine/projects/caerphilly).
The English Longitudinal Study of Ageing
(ELSA) comprises men and women aged 50 years
and over who originally participated in the Health
Survey for England in 1998, 1999 or 2001.
Fieldwork began in 2002–2003 (phase I) with two
yearly follow-ups, and in 2004–2005 (phase II),
blood samples were provided by 6,231 participants.
Details of the cohort have been published elsewhere
(Marmot et al. 2003).
The Hertfordshire Cohort Study (HCS) consists
of 2,997 participants born 1931–1939 and regis-
tered with a general practitioner in East, North or
West Hertfordshire who attended a clinic in 1994–
2004 (phase I). A second assessment took place in
2004–2005 for participants in East Hertfordshire
(phase II). Further details of the study design, data
collected and summaries of participant characteris-
tics have been published (Syddall et al. 2005) and
are available on its website (www.mrc.soton.ac.uk/
herts).
The Boyd Orr cohort is a historical cohort study
based on children surveyed in 1937–1939 in English
and Scottish districts. Participants were followed up
for vital status via the NHS Medical Information
Research Service (MIRS) since 1948, with question-
naire administration to survivors in 1997–1998
(phase II) and a research clinic visit in 2002–2003
(phase III), during which DNA was extracted from
728 adults, of which 397 of 405 who attended
specific measurement research clinics had at least
one physical capability measure and one relevant
genotype called for this analysis. Details of the study
design and the data collected have been described on
its website (http://www.bris.ac.uk/social-community-
medicine/projects/boyd-orr) and elsewhere (Martin
et al. 2005).
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The Lothian Birth Cohort 1921 (LBC1921) par-
ticipants were all born in 1921 and most complet-
ed a cognitive ability assessment at age 11 years.
In 1999–2001 (wave I), at approximately 79 years
old, 550 participants living in and around
Edinburgh, underwent a series of cognitive and
physical tests. In 2003–2005 (wave II), 321
returned at 83 years old. Details of the recruitment
into the study are available on its website (www.
lothianbirthcohort .ed.ac.uk) and have been
published previously (Deary et al. 2004b; Deary
et al. 2012).
Genotyping and quality control
Single nucleotide polymorphisms (SNPs) rs7412 and
rs429358 form the APOE genotype (ε2/ε2, ε2/ε3, ε2/
ε4, ε3/ε3, ε3/ε4 and ε4/ε4; 19q13.32) and genotyp-
ing was carried out by KBioscience (www.
lgcgenomics.com) in Boyd Orr, CaPS, HCS, NCDS
and NSHD. In ELSA, two TaqMan assays (rs429358
and rs7412, Assay-On-Demand, Applied Biosystems,
Geneservice Ltd, Cambridge, UK) were used and run
on a 7900HT analyzer (Applied Biosystems), and
genotypes indicated by the Sequence Detection
Software version 2.0 (Applied Biosystems). Details
have been described previously in LBC1921
(Schiepers et al. 2012) and Whitehall II (Sabia et al.
2010). Genotyping for other SNPs (rs515135 (APOB,
2p24.1), rs2228671 (LDLR, 19p13.2) and rs629301
(SORT1, 1p13.3)) in ELSA, HCS, CaPS and Boyd
Orr were carried out by KBioscience, as well as for
rs2228671 in NSHD. In LBC1921, information came
from the Illumina Human 610-Quadv1 Chip (using
proxies rs541041 for rs515135 and rs646776 for
rs629301) (Houlihan et al. 2010). SNPs in NCDS
came from two sources—Illumina HumanHap 550 k
v3 and Illumina 1.2 M chips (using rs562338 and
rs541041 as proxies for rs515135 and rs646776 as a
proxy for rs629301) (Wellcome Trust Case Control
Consortium 2007). Genotype information for these
three SNPs in Whitehall II as well as rs515135 and
rs2228671 in NSHD came from the Illumina
Metabochip (www.illumina.com). Genotypic data
quality was reviewed by assessing departure from
the Hardy-Weinberg equilibrium (HWE), clustering
quality (using KBioscience software SNPviewer on
their data) and call rates.
Phenotypes
Cognitive capability
A number of cognitive performance tests in the different
studies were used to assess cognitive capability.
Different assessments of verbal memory (Bopp and
Verhaeghen 2005) were conducted: in ELSA and
NCDS, a list of 10 common words were used, with
participants asked to recall the list immediately and
again after a delay of around 5 min; the mean score
was used in the analysis; in NSHD, 15 words were used
over three trials; in Whitehall II, 20 words were used;
responses in NSHD and Whitehall II were given in
writing. In Whitehall II, participants recalled in writing
in 1 min as many words as possible beginning with ‘S’
to assess phonemic fluency (Borkowski et al. 1967),
while in LBC1921 three letters ‘C’, ‘F’ and ‘L’ were
used with responses given orally. Participants were
asked to recall as many animals as possible within
1 min to measure semantic fluency (Borkowski et al.
1967); responses were given orally in ELSA, NCDS,
CaPS and NSHD, and in writing in Whitehall II. To
assess search speed (Richards et al. 1999), 1-min letter
searches among grids of letters were used, 600 letters in
NSHD and 780 in ELSA and NCDS.
Physical capability
Grip strength was measured in NSHD, ELSA, HCS and
LBC1921 using electronic or hydraulic dynamometers,
with the best measure used in the analysis where more
than one trial was conducted. Standing balance tests
were conducted in the studies, with participants’ eyes
open: flamingo (up to a maximum time of 30 s) (Sport
1993), in NSHD, HCS, Boyd Orr and CaPS, and side-
by-side, semi-tandem and full tandem (Stevens et al.
2008) in ELSA. Ability to balance was defined in this
analysis as the ability to complete 30 s of the flamingo or
5 s of the tandem test. The timed get up and go test
(Podsiadlo and Richardson 1991) was carried out in
HCS, Boyd Orr and CaPS and required participants to
get up from a chair, walk 3 m at a normal pace, turn,
walk back, turn and sit down. Timed walks over 2.44 m
(8 ft) at a normal pace and 6m at a fast pace were carried
out in ELSA and LBC1921, respectively. Speeds were
calculated for timed walks and get up and go, with the
fastest speeds used in the analysis where more than one
trial was conducted. Timed chair rises (Csuka and
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McCarty 1985) involved asking participants to rise from
a chair and sit back down 5 times in ELSA and HCS and
10 times in NSHD; the reciprocal of time taken in
seconds×100 (Kuh et al. 2005) was used in the analysis.
Further details of these measurements in these cohorts
are presented elsewhere (Cooper et al. 2011).
Statistical methods
Where information on ethnicity was collected, non-
European participants were excluded from analyses in
order to avoid confounding from population stratifica-
tion (Cordell and Clayton 2005). Within studies, linear
regression analyses were conducted on the continuous
traits and logistic regression analyses were conducted on
the ability to balance, adjusting for age, except in the age
homogeneous cohorts of NCDS, NSHD and LBC1921
as well as sex in all cohorts except CaPS. APOE geno-
type was analysed here in two ways: first, ε2+ (ε2/ε2 or
ε2/ε3) and ε4+ (ε3/ε4 or ε4/ε4) were compared with ε3/
ε3; second, ε4+ (ε3/ε4 and ε4/ε4) was compared with
non ε4 (ε2/ε2, ε2/ε3 and ε3/ε3). Due to the differences
observed on LDL-C for carriers of the ε2 and ε4 alleles
(Bennet et al. 2007), the ε2/ε4 genotype was excluded
from the APOE analysis. Additive models were used for
SNPs rs515135 (APOB), rs2228671 (LDLR) and
rs629301 (SORT1), with genotypes coded as 0, 1 and
2 for the number of LDL-raising alleles. Likelihood
ratio tests were used to compare the fit of the additive
models compared with the full genotype model. Allelic
scores were derived from counts of the number ofAPOE
ε4 or LDL-C-raising alleles. For continuous traits, the
normality of the standardised residuals was inspected
with distributional diagnostic plots. For the
harmonisation of continuous traits that were used to
obtain pooled estimates of the genotypic effects, z score
units were calculated in each study by subtracting the
study mean and dividing by its standard deviation. The
overall mean for z scores is 0 and standard deviation 1.
Two-step (Riley et al. 2010) meta-analyses using a
random-effects model were performed to obtain pooled
genotypic effects. The I2 measure was used to quantify
heterogeneity (Higgins et al. 2003). Analyses of the
interaction between ε4 carrier status and age within
studies were also conducted. Where outcomes were
collected at more than one phase, within-study analyses
were performed on the annual change in scores using
differences between the most recent and earliest mea-
sure available. Finally, the calculation of z scores, for the
continuous traits, and the main analyses were repeated in
men and women separately. Reporting of the analyses
met the appropriate items of recommended checklists
(Stroup et al. 2000; Little et al. 2009). A two-tailed
significance level of p<0.05 was used as evidence of
statistical significance. Statistical analysis was performed
in Stata 12.1 (StataCorp LP). Quanto (Gauderman and
Morrison 2006) was used for power calculations.
Results
Cohort summaries and genotyping quality
A total of 23,916 adults aged between 44 and 90+years
had at least one relevant genotype and phenotype avail-
able (Table 1). Allelic frequencies were similar across
the studies. Of the 23,061 participants with available
APOE data, the genotypic frequencies were as follows:
ε2/ε2—0.6 %, ε2/ε3—12.3 %, ε2/ε4—2.6 %, ε3/ε3—
58.5 %, ε3/ε4—23.6 % and ε4/ε4—2.4 %. The HWE
condition was met in all studies for all polymorphisms
(p values>0.1), except for rs515135 (APOB) and
rs2228671 (LDLR) in NSHD and rs515135 (APOB) in
ELSA (p values=0.04). Summaries of measures of cog-
nitive and physical capability are presented in Table S1.
Associations between APOE genotypes and cognitive
capability
Figures S1–S4 present the associations between the
cognitive capability measures and ε2+ and ε4+,
adjusting for age and sex, using ε3/ε3 as the reference
group in the cross-sectional analyses. There was no
evidence for associations in the pooled analyses.
Within studies, there was evidence for negative effects
of ε2+ and ε4+ in NSHD and ELSA, respectively, on
word recall (Figure S1), and of ε2+ in ELSA on seman-
tic fluency (Figure S3). Table 2 shows that there was no
evidence for associations between APOE and the cog-
nitive capability measures when comparing carriers of
the ε4 allele with noncarriers. Table S2 presents the
findings of the interactions between the ε4 allele and
age within the studies. In ELSA, there was some evi-
dence that a negative effect of ε4 on word recall in-
creases with age (p value=0.04) and borderline evi-
dence for this on search speed (p value=0.08). There
was some evidence that the effects of ε4 allele on word
recall differs between men and women (p value for
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heterogeneity=0.009; Figure S5). There was no evi-
dence for heterogeneity between men and women for
other outcomes (p values>0.1; data not shown). For the
few studies with data available, there was no strong
evidence that the ε4 allele was associated with cognitive
decline within the time periods investigated (Table S3).
Associations between APOB, LDLR and SORT1
genotypes and cognitive capability
There was some evidence that the LDL-C-raising allele
of rs2228671 (LDLR) was associated with lower seman-
tic fluency scores (Table 2, Figure S6). There was no
evidence for any other associations between the SNPs
and measures of cognitive capability (Table 2). Table S4
that shows there was no evidence for associations be-
tween any of the measures and the allelic count of the
number of LDL-C-raising and ε4 alleles. There was no
evidence for differences in genotypic effects by sex for
the SNPs (p values>0.06; data not shown).
Associations between APOE genotypes and physical
capability
Figures S7 to S10 show that there was no strong evidence
of associations in the pooled analyses between the phys-
ical capability measures and ε2+ and ε4+ adjusting for
age and sex, compared with ε3/ε3 in the cross-sectional
analyses. Within studies, there was evidence in ELSA
that participants with ε4+ had slower chair rise times than
those with ε3/ε3 (Figure S9). There was no evidence that
carriers of ε4 had poorer performance than noncarriers in
the pooled analyses (Table 3). Table S5 shows that there
was no evidence for interactions between the ε4 allele
and age within the studies. There was no evidence for
heterogeneity between men and women in the effects of
the ε4 allele for these measures (p values>0.6; data not
shown). In the longitudinal analyses, there was evidence
in ELSA that the ε4 allele was associated with decline in
timed walk speed (p value=0.02; Table S6).
Associations between APOB, LDLR and SORT1
genotypes and physical capability
Table 3 shows that there was no evidence for associa-
tions between the SNPs and measures of physical capa-
bility. Table S7 shows that there was evidence for asso-
ciations between the allelic count of the number of LDL-
C-raising and ε4 alleles and poorer timed chair rises (p
value=0.01). There was some evidence that the effect of
the C allele of rs515135 (APOB) on timed chair rises
differed by sex, with an inverse association observed in
females only (p value for heterogeneity=0.01;
Figure S11). There was also evidence for heterogeneity
by sex for the effects of rs2228671 (LDLR) on ability to
balance (p value for heterogeneity=0.04; Figure S12).
Table 1 Summary of sex, age and LDL-related genotypes by cohort
Cohort
Characteristic NCDS NSHD Whitehall
II
CaPS ELSA HCS Boyd Orr LBC1921 Total
Number of participants 7,363 2,674 3,143 1,318 5,612 2,893 397 516 23,916
Male, % 50 50 77 100 46 53 45 41 55
Agea in years, median
(range)
44 53 59 (50–73) 61 (52–
71)
65 (52–
90+)
66 (59–
73)
70 (64–
82)
79 (77–
80)
56 (44–
90+)
APOE ε4 carrier statusb, % 27 28 26 26 26 26 27 24 27
LDL-C-raising allele frequency
rs515135 APOB, C 0.82 0.82 0.82 0.82 0.82 0.82 0.82 0.85 0.82
rs2228671 LDLR, C 0.87 0.88 0.87 0.88 0.88 0.88 0.88 0.88 0.87
rs629301 SORT1, A 0.78 0.77 0.79 0.77 0.78 0.78 0.77 0.75 0.78
Number of participants represents those with available data for at least one phenotype and at least one genotype
CaPSCaerphilly Prospective Study, ELSA English Longitudinal Study of Ageing,HCSHertfordshire Cohort Study, LBC1921 Lothian Birth
Cohort 1921, NCDS National Child Development Study, NSHD National Survey of Health and Development
a Age at phase from which the majority of variables are taken, i.e. Boyd Orr: III; CaPS: III; ELSA: II; HAS: I; HCS: I; LBC1921: I; NCDS:
Biomedical Survey (2002); NSHD: 1999 Collection; Whitehall II: VII
b ε4 carrier defined as ε3/ε4 or ε4/ε4; ε2/ε4 excluded from denominator
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Table 2 Summary of pooled associations between LDL-C-related genotypes and cognitive capability
Measure Genotype Beta (95 % CI) p I2 %; Het p N
APOE ε4 −0.01 (−0.06–0.04) 0.67 46.0; 0.14 17,513
rs515135 APOB −0.02 (−0.04–0.01) 0.23 0.0; 0.67 16,473
Word recall rs2228671 LDLR 0.01 (−0.02–0.04) 0.49 0.0; 0.97 16,481
rs629301 SORT1 0.01 (−0.02–0.03) 0.52 0.0; 0.97 16,494
APOE ε4 −0.01 (−0.16–0.14) 0.89 53.6; 0.14 3,528
Phonemic fluency rs515135 APOB 0.00 (−0.07–0.07) 0.96 7.8; 0.30 3,638
rs2228671 LDLR −0.03 (−0.10–0.05) 0.52 6.8; 0.30 3,638
rs629301 SORT1 −0.01 (−0.06–0.05) 0.83 0.0; 0.88 3,636
APOE ε4 −0.02 (−0.05–0.02) 0.31 0.0; 0.98 18,796
Semantic fluency rs515135 APOB −0.02 (−0.05–0.01) 0.16 0.0; 0.97 17,761
rs2228671 LDLR −0.03 (−0.06–0.00) 0.048 0.0; 0.51 17,766
rs629301 SORT1 0.01 (−0.04–0.05) 0.83 66.8; 0.02 17,774
APOE ε4 0.00 (−0.05–0.06) 0.91 54.6; 0.11 14,348
Search speed rs515135 APOB −0.02 (−0.05–0.01) 0.26 0.0; 0.82 13,229
rs2228671 LDLR 0.01 (−0.02–0.05) 0.54 0.0; 0.81 13,235
rs629301 SORT1 0.00 (−0.05–0.05) 0.90 64.7; 0.06 13,250
Coefficients based on z scores and adjusted for age and sex. Coefficients for APOE ε4+: carrier vs. non-ε4 carrier; else per LDL-C-raising allele
Table 3 Summary of pooled associations between LDL-C-related genotypes and physical capability
Measure Genotype Beta (95 % CI) p I2 %; Het p N
APOE ε4 0.01 (−0.02–0.05) 0.42 30.7; 0.23 10,646
Grip strength rs515135 APOB 0.00 (−0.04–0.03) 0.81 41.5; 0.16 11,247
rs2228671 LDLR 0.01 (−0.01–0.04) 0.40 0.0; 0.65 11,234
rs629301 SORT1 −0.01 (−0.03–0.02) 0.61 34.1; 0.21 11,242
Get up and go/walk speed APOE ε4 −0.02 (−0.07–0.04) 0.57 7.8; 0.36 6,810
rs515135 APOB 0.00 (−0.05–0.06) 0.90 30.6; 0.22 7,291
rs2228671 LDLR 0.04 (−0.06–0.13) 0.47 67.6; 0.01 7,277
rs629301 SORT1 0.01 (−0.03–0.04) 0.73 0.0; 0.42 7,281
Timed chair rises APOE ε4 −0.04 (−0.10–0.02) 0.18 37.8; 0.20 8,159
rs515135 APOB −0.03 (−0.07–0.01) 0.11 0.0; 0.85 8,601
rs2228671 LDLR 0.00 (−0.05–0.04) 0.86 2.4; 0.36 8,598
rs629301 SORT1 −0.02 (−0.06–0.01) 0.16 0.0; 0.47 8,601
Genotype OR (95 % CI) p I2 %; Het p n/N
Ability to balance ≥5 s APOE ε4 1.02 (0.88–1.17) 0.80 0.0; 0.63 8,696/10,114
rs515135 APOB 1.01 (0.91–1.13) 0.86 0.0; 0.67 9,131/10,654
rs2228671 LDLR 1.04 (0.92–1.18) 0.54 0.0; 0.70 9,122/10,643
rs629301 SORT1 0.97 (0.87–1.07) 0.49 0.0; 0.92 9,139/10,652
Coefficients for continuous outcomes based on z scores. Adjusted for age and sex. Coefficients forAPOE ε4+: carrier vs. non-ε4 carrier; else
per LDL-C-raising allele
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Discussion
In this investigation of 23,916 adults aged between 44
and 90+ from eight UK cohorts, we examined the ge-
notypic effects of the APOE ε2/3/4 genotype on mea-
sures of cognitive and physical capability, as well as
those of three other LDL-C-related genotypes: rs515135
(APOB), rs2228671 (LDLR) and rs629301 (SORT1).
For the four cognitive capability measures studied (word
recall, phonemic fluency, semantic fluency and search
speed), we found little evidence for associations with
APOE genotype (Table 2). However, within-study in-
vestigations into interactions between ε4 and age pro-
vided suggestive evidence for an adverse effect of ε4 on
word recall that increased with age (p value=0.044, n=
4,971) as well as suggestive evidence for this on search
speed in the largest age-heterogeneous cohort (p value=
0.08, n=4,901; Table S2). In the longitudinal analyses,
we observed no evidence that the ε4 allele was associ-
ated with cognitive decline. Investigations into the other
genotypes revealed only borderline evidence for an
association between the LDL-C-raising allele of
rs2228671 (LDLR) and reduced semantic fluency (p
value=0.048, n=17,766). There was little evidence to
support associations between the APOE genotype and
our physical capability measures (grip strength, timed
get up and go/walk speed, timed chair rises and ability to
balance) in the cross-sectional analysis and no evidence
that genotypic effects vary by age. In the longitudinal
analysis, there was evidence from ELSA that the ε4
allele was associated with decline in timed walk speeds
(p value=0.02, n=2,195; Table S6). We found little
evidence for associations between the other LDL-C-
related genotypes and physical capability (Table 3).
Previous investigations into associations between the
APOE genotype and measures of cognitive performance
have produced mixed findings, possibly reflecting dif-
ferences in cognitive domains and age (Wisdom et al.
2011). Meta-analyses of previous studies have found
evidence for small adverse effects of the ε4 allele on
some cognitive domains, including episodic memory, as
well as evidence that this effect may increase with age
(Wisdom et al. 2011). An increasing effect with age has
also been seen in a study of over 10,000 Korean older
adults (Shin et al. 2014). However, no evidence was
found for effects onmeasures on verbal ability (Wisdom
et al. 2011). Results from our investigations on APOE
are consistent with many of those findings, with evi-
dence for an interaction between ε4 and age on a
measure of episodic memory and word recall and no
evidence for any effects on our measures of verbal
ability: semantic and phonemic fluency. Previous stud-
ies have observed a greater cognitive decline among
carriers of the ε4 allele compared with noncarriers; in
particular, there is evidence from a middle-aged cohort
for differences in delayed word recall over 6 years (Blair
et al. 2005), and a longitudinal study showed that de-
clines inmemory scoresmay be apparent before 60 years
(Davies et al. 2014). Our own investigation from the
model in ELSA suggested a detectable difference from
around 55 years. Fewer investigations have been report-
ed on the associations between APOE and measures of
physical performance; however, findings include no
association with athletic performance (Tsianos et al.
2010) and associations between ε4 and slower gait
speeds from a study of 1,262 adults aged over 65 years
(Melzer et al. 2005). Our larger investigation found
evidence to support a role of APOE in decline in walk
speeds over a 4-year period in one study but little
evidence for associations with physical capability from
cross-sectional analysis. Differences have been ob-
served in the genotypic frequencies of rs11668477 in
LDLR for mild cognitive impairment status in a small
study of 114 cases and 92 controls (Liu et al. 2012). We
believe that this is the largest investigation between
APOB, LDLR and SORT1 genotypes and measures of
cognitive and physical performance.
Our large investigation into associations between
the APOE genotype on cognitive capability measures
provided only modest evidence for an adverse effect
of the ε4 allele. There was also little evidence from
the three other investigated LDL-C-related genotypes,
suggesting that the small effects of APOE observed
previously on some cognitive measures in population-
based studies may not extend to genotypes implicated
in LDL-C levels as a whole. However, the lack of
evidence from our studies for these other SNPs may
reflect a lack of power to observe possible small
effects. Sample size calculations demonstrated around
11,000 individuals would be required to detect a beta
coefficient of 0.05 z score units with 80 % power at
the 5 % significance level for a SNP such as
rs515135 (APOB) using an observed minor allele
frequency of 0.18. We were sufficiently powered to
detect differences as small as this for three of our
cognitive measures; however, the observed pooled
coefficients were much smaller. There are
hypothesised mechanisms through which APOE may
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affect cognitive performance in non-demented adults
other than through LDL-C, for instance, ε4/ε4 has
been associated with increased rate of hippocampal
volume loss (Crivello et al. 2010) and increased white
matter hyperintensity burden (Schilling et al. 2013).
Furthermore, APOE has been associated with several
other ageing phenotypes (Khan et al. 2013). Our
results suggest that these mechanisms might not lead
to cognitive differences at a population level. Similar
to the reports on cognitive performance (Yaffe et al.
2002; Packard et al. 2007), associations between
measures of LDL-C and physical performance in the
literature have been mixed, with higher levels associ-
ated with slower walking speeds (Walston et al.
2002), but some evidence that it may be protective
against frailty (Blain et al. 2012). Our findings from
other LDL-C-related genotypes suggest that LDL-C
may not be an important mechanism through which
APOE could affect physical performance. However,
other potential pathways include the modest effects
on specific cognitive measures and their decline and
effects on bone-related phenotypes, though evidence
for the latter is inconsistent (Peter et al. 2011;
Tolonen et al. 2011).
Despite the size of our study, large age range and the
inclusion of other LDL-C-related genotypes, there are
some limitations. First, our ability to detect effects of our
genotypes on decline in cognitive and physical capabil-
ity may have been hindered by generally short intervals
between measures in the cohorts (often around four
years). Second, despite the important cognitive mea-
sures included here, there may be other cognitive do-
mains which may be influenced by the APOE genotype.
Third, although we only observed modest evidence for a
detrimental impact of the ε4 allele on cognitive out-
comes, it is possible that an effect may be influenced a
likely higher proportion of preclinical dementia cases
among the ε4 carriers. However, it is possible that
APOE also affects non-pathological cognitive ageing
(Davies et al. 2014). Fourth, we did not conduct inves-
tigations into the differential effects among each of the
six APOE genotypes; however, given we observed only
modest evidence for differences between ε4 and non-ε4
carriers, it is unlikely that this study would have been
sufficiently powered to observe any of the putatively
smaller differences. Furthermore, larger meta-analyses
were unable to detect differences between the effects of
ε3/ε4 and ε4/ε4 on several cognitive domains (Wisdom
et al. 2011).
Conclusion
This large, multi-cohort investigation into associations
between APOE ε2/3/4 genotype, three other LDL-C-
related SNPs and measures of cognitive and physical
capability provided little support for anything but mod-
est effects of these genotypes on these traits in middle-
aged to older adults.
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